By E. Janene Geiss
Philadelphia, July 24 - Ambrx, Inc. said Monday that it has raised an additional $3 million in a series C financing round.
The Scottish Widows Investment Partnership was the lead investor, bringing the total secured in the company's series C financing to $55 million, according to a company news release.
Net proceeds will be used to further expand Ambrx's novel protein modification platform, to support the development of its product pipeline and for general working capital purposes.
Ambrx is a San Diego biopharmaceutical company focused on optimizing existing protein drugs.
| Issuer: | Ambrx, Inc.
|
| Issue: | Series C financing
|
| Amount: | $3 million
|
| Investors: | Scottish Widows Investment Partnership
|
| Announcement date: | July 24
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
